About Sepracor
Sepracor is a Healthcare company based in Marlborough (United States) founded in 1984, and was acquired by Sumitomo Dainippon Pharma in September 2009. It operates as a pharmaceutical products for respiratory and CNS disorders are developed. Its chief executive is Saburo Hamanaka. Sepracor offers products and services including Drug Pipeline and Clinical Trials. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Sumitomo Pharma America, Inc.
Company details
In July 2010, Sepracor and Dainippon Sumitomo Pharma (DSP), an Osaka, Japan-based pharma company, announced the intent to change the Sepracor name to Sunovion Pharmaceuticals. DSP acquired Sepracor in October 2009 and the name change was planned to occur in anticipation of the one-year anniversary of the acquisition. Sepracors drug development program, together with its corporate development and licensing efforts, has yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders. Currently, marketed products include LUNESTA brand eszopiclone, XOPENEX brand levalbuterol HCl Inhalation Solution, XOPENEX HFA brand levalbuterol tartrate Inhalation Aerosol, BROVANA brand arformoterol tartrate Inhalation Solution, OMNARIS brand ciclesonide Nasal Spray and ALVESCO brand ciclesonide HFA Inhalation Aerosol.
- Headquarters Marlborough, United States
- SectorsHealthcare
- Website sepracor.com
- Social LinkedIn
- Acquired by Sumitomo Dainippon Pharma (Sep 2009)
- Legal Name Sumitomo Pharma America, Inc.
- Investors
- Acquired bySumitomo Dainippon Pharma
(Sep 2009)
Products & Services of Sepracor
Sepracor offers a comprehensive portfolio of products and services, including Drug Pipeline and Clinical Trials.
Advances preclinical and clinical programs for various health needs
Conducts trials to develop treatments for rare diseases and more
Investors in Sepracor
Sepracor has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sumitomo Dainippon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured. | 1897 | ds-pharma.com | Osaka, Japan |
Investor details for Sepracor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sepracor
1 people are tracked at Sepracor (1 in leadership).
| Name | Role | Group |
|---|---|---|
Saburo Hamanaka | CEO | Leadership |
Complete people profiles for Sepracor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sepracor
2 dated milestones of Sepracor across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Sepracor is founded.
- Exit Acquired by Sumitomo Dainippon Pharma.
Web traffic of Sepracor
Websites that share an audience with Sepracor (sepracor.com).
Websites whose visitors overlap most with Sepracor. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sunovion.com | 100% | 11.4K | #4,229,536 | View details | |
| merck.com | 98% | 656.8K | #78,842 | View details | |
| bayer.com | 98% | 1.1M | #52,188 | View details | |
| astrazeneca.com | 98% | 1.3M | #48,983 | View details | |
| wyeth.com | 98% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 30 similar websites and full traffic analytics for Sepracor
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 30 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Sepracor (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sepracor
Sepracor was founded in 1984.
Sepracor is headquartered in Marlborough, United States. It is registered at Marlborough, Massachusetts, United States.
Saburo Hamanaka is the current CEO of Sepracor.
In July 2010, Sepracor and Dainippon Sumitomo Pharma (DSP), an Osaka, Japan-based pharma company, announced the intent to change the Sepracor name to Sunovion Pharmaceuticals. DSP acquired Sepracor in October 2009 and the name change was planned to occur in anticipation of the one-year anniversary of the acquisition. Sepracors drug development program, together with its corporate development and licensing efforts, has yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders. Currently, marketed products include LUNESTA brand eszopiclone, XOPENEX brand levalbuterol HCl Inhalation Solution, XOPENEX HFA brand levalbuterol tartrate Inhalation Aerosol, BROVANA brand arformoterol tartrate Inhalation Solution, OMNARIS brand ciclesonide Nasal Spray and ALVESCO brand ciclesonide HFA Inhalation Aerosol.
Sepracor offers Drug Pipeline and Clinical Trials.
Sepracor has 1 investor. Key investors include Sumitomo Dainippon Pharma.
Sepracor operates through Sumitomo Pharma America, Inc..
Yes. Sepracor was acquired by Sumitomo Dainippon Pharma in September 2009.